The Effect of Adiponectin-Leptin Ratio on Weight Loss in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity

NCT07564973 | Completed

• 1 other identifier: 2024-KAEK-11 284
• Study Type: observational
• Target: 78
• Locations: 1 country
• Sites: 1

Brief Summary

Our study aims to find out if a specific blood test, measuring the balance between two hormones (adiponectin and leptin), can predict how much weight a person might lose after sleeve gastrectomy, a surgery for obesity. We want to see if this hormone ratio can help identify who will benefit most from the surgery. If we find that people with a low hormone ratio are less likely to lose weight after surgery, doctors can guide them toward other weight-loss options, like lifestyle changes or different treatments, instead of surgery. This way, patients can get the care that's best for them.

Conditions

Morbid Obesity Requiring Bariatric Surgery

Keywords

morbid obesity; bariatric surgery; sleeve gastrectomy; Adiponectin; Leptin; Adiponectin-Leptin Ratio

Outcome Measures

Primary Outcomes (1)

• Change in body mass index at 8 months

  8 months after surgery

Secondary Outcomes (1)

• Change in lipid profile at 8 months

  8 months after surgery

Study Arms (1)

Sleeve Gastrectomy Patients

Patients who meet inclusion criteria for the study undergoing sleeve gastrectomy

Procedure: Laparoscopic Sleeve Gastrectomy

Interventions

Laparoscopic Sleeve Gastrectomy PROCEDURE

Laparoscopic Sleeve Gastrectomy

Sleeve Gastrectomy Patients

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients applying to Başakşehir Çam Sakura City Hospital General Surgery Clinic for bariatric surgery

You may qualify if:

• Patients aged 18 to 75
• International Classification of Diseases (ICD) code E66 diagnosis (obesity)
• Patients who have given consent for sleeve gastrectomy
• Patients who are suitable for general anesthesia

You may not qualify if:

• Patients who did not give consent to be included in the study
• Patients who are scheduled for surgery other than sleeve gastrectomy

Sponsors & Collaborators

• Sercan YUKSEL, MD: lead

Study Sites (1)

Basaksehir Cam and Sakura City Hospital

Istanbul, Basaksehir, 34480, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood will be centrifuged and serum will be stored separately in eppendorf tubes.

MeSH Terms

Conditions

Obesity, Morbid

Condition Hierarchy (Ancestors)

Obesity; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: April 27, 2026
• First Posted: May 4, 2026
• Study Start: January 1, 2025
• Primary Completion: March 31, 2026
• Study Completion: April 27, 2026
• Last Updated: May 4, 2026

Record last verified: 2026-04

Locations

TU (1)